BACKGROUND: Previous studies indicate that heparanase (HPA), an endoglycosidase involved in tumor angiogenesis and metastasis, is up-regulated in a variety of malignancies. However, the expression of HPA in neuroblastoma (NB), one of the most common extra cranial solid tumors in children, remains unknown. This study was undertaken to explore the expression and clinical significance of HPA in NB. METHODS: Immunohistochemical staining was applied to detect the expression of HPA in 42 cases of NB. The relationships among HPA expression, international neuroblastoma staging system (INSS) stages, histopathological classification, and postoperative survival of the NB patients were analyzed. RESULTS: The expression rate of HPA in NB was 61.9% (26/42), mainly in the cytoplasm of neuroblastoma cells. The expression rates of stage 1-2, stage 3-4 and stage 4S were 35.7%, 80.0% and 62.5%, respectively. The differences between stage 1-2 and stage 3-4 were significant (P<0.01). The expression of HPA was significantly higher in the NB cases that had one of the histopathological factors: age more than 1 year (P<0.01), poorer differentiation (P<0.01), and higher mitosis karyorrhexis index (P<0.01). The survival time of HPA-negative patients was significantly longer than that of HPA-positive patients (P<0.05). CONCLUSION: Although these results indicate that heparanase might be correlated with development and progression of NB, a larger series of patients with a longer follow-up are probably needed to strengthen its role in assessment of NB prognosis.
BACKGROUND: Previous studies indicate that heparanase (HPA), an endoglycosidase involved in tumor angiogenesis and metastasis, is up-regulated in a variety of malignancies. However, the expression of HPA in neuroblastoma (NB), one of the most common extra cranial solid tumors in children, remains unknown. This study was undertaken to explore the expression and clinical significance of HPA in NB. METHODS: Immunohistochemical staining was applied to detect the expression of HPA in 42 cases of NB. The relationships among HPA expression, international neuroblastoma staging system (INSS) stages, histopathological classification, and postoperative survival of the NB patients were analyzed. RESULTS: The expression rate of HPA in NB was 61.9% (26/42), mainly in the cytoplasm of neuroblastoma cells. The expression rates of stage 1-2, stage 3-4 and stage 4S were 35.7%, 80.0% and 62.5%, respectively. The differences between stage 1-2 and stage 3-4 were significant (P<0.01). The expression of HPA was significantly higher in the NB cases that had one of the histopathological factors: age more than 1 year (P<0.01), poorer differentiation (P<0.01), and higher mitosis karyorrhexis index (P<0.01). The survival time of HPA-negative patients was significantly longer than that of HPA-positive patients (P<0.05). CONCLUSION: Although these results indicate that heparanase might be correlated with development and progression of NB, a larger series of patients with a longer follow-up are probably needed to strengthen its role in assessment of NB prognosis.
Authors: H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry Journal: Cancer Date: 1999-07-15 Impact factor: 6.860
Authors: Xiaotong He; Paul E C Brenchley; Gordon C Jayson; Lynne Hampson; John Davies; Ian N Hampson Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: J Rohloff; J Zinke; K Schoppmeyer; A Tannapfel; H Witzigmann; J Mössner; C Wittekind; K Caca Journal: Br J Cancer Date: 2002-04-22 Impact factor: 7.640
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: K Dredge; E Hammond; P Handley; T J Gonda; M T Smith; C Vincent; R Brandt; V Ferro; I Bytheway Journal: Br J Cancer Date: 2011-02-01 Impact factor: 7.640